Presentation is loading. Please wait.

Presentation is loading. Please wait.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Published byDeddy Pranoto Modified over 5 years ago

Similar presentations

Presentation on theme: "Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor."— Presentation transcript:

1 Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Weekly treatment with Pz1+ T cells in mice bearing systemic NALM-6 (GFP-FFLuc) resulted in a typical diffuse pattern of tumor cell expansion involving the bone marrow, spleen, liver, lymph nodes, and periodontal regions (A). All mice developed lethal disease 4 to 5 wks after tumor cell injection. Mice treated weekly with 19z1+ T cells showed persistent or relapsed disease at distinct anatomic sites including the bone marrow (B), periodontal region, CNS/calvarium, abdomen, and spleen (data not shown). Treatment failure in 19-28z+ T cell–treated mice likewise occurred at distinct but disparate anatomic sites including the spleen (C), CNS/calvarium (D), periodontal region (E), and bone marrow (F). Renier J. Brentjens et al. Clin Cancer Res 2007;13: ©2007 by American Association for Cancer Research

Download ppt "Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor."

Similar presentations

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
BV6 increases tumor burden in bone.

BV6 increases tumor burden in bone.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.

In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
MicroPET and CCD imaging of β-cells in MIP-TF mice.

MicroPET and CCD imaging of β-cells in MIP-TF mice.
Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
IL6 mRNA is not detected in metastatic prostate cancer cells.

IL6 mRNA is not detected in metastatic prostate cancer cells.
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

Similar presentations

Ads by Google